SEC Form 4 · accession 0001179110-15-006865
ACCELERON PHARMA INC · XLRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ravindra Kumar
Officer — VP & Chief Scientific Officer
Period of report
Apr 28, 2015
Accepted (ET)
Apr 30, 2015 · 5:02 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001280600
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Apr 28, 2015 | M | 5,000 | $1.80 | A | 38,200 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase Common StockF1 | $1.80 | Apr 28, 2015 | M | 5,000 | D | — | Jun 12, 2017 | Common Stock | 5,000 | 2,300 | D |
Explanation of responses
- F1The options of registrant's common stock vested in equal quarterly installments over the first four years after the grant.